Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002231331 | SCV000631599 | likely benign | Ehlers-Danlos syndrome, classic type, 1 | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000541739 | SCV000895373 | uncertain significance | Ehlers-Danlos syndrome, classic type | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001093164 | SCV001250013 | uncertain significance | not provided | 2022-07-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001093164 | SCV002002591 | uncertain significance | not provided | 2023-11-27 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 33974636) |
Ambry Genetics | RCV002456081 | SCV002617636 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2021-11-17 | criteria provided, single submitter | clinical testing | The p.P1220S variant (also known as c.3658C>T), located in coding exon 51 of the COL5A2 gene, results from a C to T substitution at nucleotide position 3658. The proline at codon 1220 is replaced by serine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |